Xeris Biopharma: Strong Recorlev Momentum And Pipeline Opportunity
Source: SeekingAlpha
2026-02-03 08:52:33 ET
Xeris Pharmaceuticals' ( XERS ) shares have surged nearly 100% year-over-year (YoY) as a result of both strong and accelerating commercial revenue growth, improving operational discipline, and positive results from its pipeline. Today, Xeris represents more than just a development-stage biotechnology company; it has transformed into a commercial specialty pharmaceutical business with several successful products and a clear pathway to further growth....
Read the full article on Seeking Alpha
For further details see:
Xeris Biopharma: Strong Recorlev Momentum And Pipeline Opportunity
Recordati Industria Chim
NASDAQ: RCDTF
RCDTF Trading
0.0% G/L:
$56.95 Last:
100 Volume:
$56.95 Open:
RCDTF Latest News
February 17, 2026 12:18:11 pm
RECORDATI REPORTS STRONG PRELIMINARY FULL YEAR 2025 RESULTS: REVENUE +11.8%, EBITDA(1) +14.5%, ADJUSTED NET INCOME(2) +14.5%
January 29, 2026 05:19:55 pm
RECORDATI ANNOUNCES STRATEGIC COLLABORATION WITH MODERNA TO DEVELOP AND COMMERCIALIZE WORLDWIDE mRNA 3927 FOR THE TREATMENT OF PROPIONIC ACIDEMIA
